Clinical Trial Update: Open Label Extension Study of AMG 531 in Japanese Subjects With ITP [Phase 2, Phase 3]

View source ↗

Summary

Open-label extension study of AMG 531 in Japanese subjects with immune thrombocytopenic purpura (ITP) completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura
• Immune Thrombocytopenia

Drugs mentioned

• AMG 531 (AMG531)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-01-21